◆ 会议时间:2025年12月10-12日
◆ 会议简介: 2025年ESMO免疫肿瘤学大会将于2025年12月10-12日在英国伦敦举行,会议由欧洲肿瘤内科学会(ESMO)组织。ESMO免疫肿瘤学大会是一个全球性会议,从免疫疗法的基础知识到最新的研究结果;从了解不同的治疗方案到毒性的管理和最新数据的解读,ESMO免疫肿瘤学大会将满足对癌症治疗这一热门领域感兴趣的肿瘤学利益相关者的不同需求。 欧洲肿瘤内科学会(ESMO)成立于1975年,是全球领先的肿瘤内科学专业组织。ESMO是肿瘤学教育和信息的参考学会,现在全球160多个国家和地区拥有超过25,000余名会员;ESMO致力于通过宣促进多学科的癌症护理,支持肿瘤学家的专业发展以及在全球倡导可持续的癌症护理,尽而为癌症患者提供最佳的护理。未经许可禁止复制摘录转载本站任何内容-国际医学会议网(lingyuint.com) ESMO Immuno-Oncology Congress 2025 Date: 10-12 December 2024 Organized by: European Society for Medical Oncology
Save the date for the ESMO Immuno-Oncology Congress 2025, taking place from 10 until 12 December 2025 as an onsite event in London, UK, as well as online. This international event provides valuable knowledge: from basic science to translational research and clinical development, cutting-edge science, and excellent networking opportunities. Take part in this meeting to learn, share your research and expertise and connect with the stakeholders that are making a difference in the field.
下为上届信息 摘要征文投稿: Abstract submission deadlines
*A preliminary abstract indicating the data expected to be available by the LBA deadline must be submitted online by 26 September 2023 as an “intent to submit a late-breaking abstract”.
Outcome notificationsOutcome notifications of regular abstracts are expected to be made available to first authors and submitters by end-October 2024. Outcome notifications of accepted full LBAs are expected to be made available to first authors and submitters by mid-Nov 2024. Information for presentersDetailed instructions for the preparation of slide presentations and/or posters will be made available by end-October in the section “Information for Presenters”. Abstract submission categories
Late-breaking abstractsLate-breaking abstracts may be submitted for high quality, new research findings with implications for clinical practice or understanding of disease processes. The final late-breaking abstract deadline of 6 November 2024 is under no circumstances to be considered as an extension of the general submission deadline (1 October 2024). Trial in Progress abstractsTrial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to the ESMO Immuno-Oncology Congress 2024. It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis. Presentation and publication of accepted abstractsThe ESMO Immuno-Oncology Congress 2024 Scientific Committee will select abstracts for presentation during the Congress and determine the format of the presentations from the following possibilities:
Accepted abstracts, including late-breaking abstracts, will be published online only in the ESMO Immuno-Oncology Congress 2024 Abstract Book, a supplement to the official ESMO journal, ESMO IOTECH. Publication schedule of accepted abstractsDetails regarding the publication of accepted abstracts are available here. ESMO Merit Travel GrantA restricted number of ESMO Merit Travel Grants to the the ESMO Immuno-Oncology Congress 2024 are available, upon application, to first author (= presenter) who submit abstracts considered to be deserving of recognition. Candidates must be ESMO Members under the age of 40. Selection will be made by the the ESMO Immuno-Oncology Congress 2024 Scientific Committee on a competitive basis from among the accepted abstracts.
注册费: Onsite participation includes:
Online participation includes:
Please note that until 20 November 2024 an onsite registration can be changed to online and vice versa, at no additional charge. Registration fees and deadlinesIndividual registration will remain open for the duration of the meeting. The ESMO Congress Secretariat must receive one completed registration per participant and the corresponding payment in EUR by the given deadlines. ESMO membership must be active seven (7) days prior to the registration deadline for the reduced member registration fee to be applied. Please visit membership page to check eligibility criteria, benefits, and to complete the membership application.
* Applicable to ESMO members from developing countries only.
WebcastsThe official sessions and Industry Satellite Symposia will be available on-demand on the Congress Virtual Platform until 16 December at 12:00 CET, for all registered participants. Once the Congress Virtual Platform is closed, the on-demand content will be transferred to OncologyPRO. Sessions from the official congress programmeRegistered delegates and ESMO Members can access resources on OncologyPRO from 16 December 2024 for 2 years. Satellite SymposiaSatellite Symposia webcasts will be available on OncologyPRO or ESMO website (only if permission has been granted by the Pharma Company) for ESMO members and registered delegates, from 16 December 2024 for 2 years. ConfirmationBy end-November 2024 delegates will receive the registration confirmation email and instructions on how to access the ESMO Immuno-Oncology Congress 2024. Health & SafetyHealth and safety measures at ESMO Immuno-Oncology Congress 2024 will be in place according to the latest local authority guidelines and requirements. Further information will be available on our website soon. Travel insuranceESMO requires recipients to purchase travel protection. Travel insurance is mandatory in order to protect delegates from the high cost of potential cancellation due to circumstances beyond the control of the congress organizer.
|
© 版权声明
本文由分享者转载或发布,内容仅供学习和交流,版权归原文作者所有。如有侵权,请留言联系更正或删除。